Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1642 1646 1671 1672 1674
This examiner grants 32% of resolved cases
Michael D Allen, in Tech Center 1600 and Art Unit 1600, has 494 resolved cases. The allowance rate is 32.0 percent, which is low and suggests a difficult examination process. This 32.0 percent rate indicates that many of the 494 cases do not result in a grant. Practitioners should be prepared for a challenging path.
The interview lift is 49.4 percent, making interviews a critical strategy for any applicant. This high lift indicates that verbal communication can significantly improve the chances of success compared to the 32.0 percent baseline. The median days to allowance is 1343, reflecting a long path to a patent grant. Applicants should factor the 1343-day timeline into their planning. The 49.4 percent lift is the most effective tool available for overcoming rejections and securing an allowance from this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18017726 | IMPROVED AAV-MEDIATED X-LINKED RETINOSCHISIS THERAPIES | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18974619 | HYBRID FLU-CORONAVIRUS VACCINE | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17997875 | DETECTION ASSAY FOR SARS-COV-2 VIRUS | Final Rejection | The Regents of the University of California |
| 18274641 | FC-ENHANCED ANTIBODIES FOR PREVENTION AND TREATMENT OF EBOLA VIRUS INFECTION | Non-Final OA | The General Hospital Corporation |
| 17271403 | CHIMERIC ONCOLYTIC HERPESVIRUS THAT STIMULATES AN ANTITUMOR IMMUNE RESPONSE | Final Rejection | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 17393742 | COMPOSITIONS AND METHODS FOR THE SIMULTANEOUS DETECTION OF INFLUENZA A, INFLUENZA B, AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) | Final Rejection | Roche Molecular Systems, Inc. |
| 18355297 | COMPOSITIONS AND METHODS FOR DETECTING HEV NUCLEIC ACID | Non-Final OA | Gen-Probe Incorporated |
| 17785223 | REASSORTED ISA VIRUS | Final Rejection | Intervet Inc. |
| 17927548 | Adenovirus-Based SARS-CoV-2 Vaccine | Final Rejection | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18593320 | METHODS OF TREATMENT OF HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) | Non-Final OA | Inovio Pharmaceuticals, Inc. |
| 18466251 | VACCINE COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | ExcepGen Inc |
| 18263462 | CHIMERIC ADENOVIRAL VECTORS | Non-Final OA | Vaxart, Inc. |
| 18349083 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | Non-Final OA | ViroMissile, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy